title: Should levodopa be used anymore?
abstract: Levodopa is the most potent dopaminergic oral drug available in clinical practice. After chronic treatment, many patients with Parkinson's disease develop dyskinesia and motor fluctuations which are difficult to manage. It was hoped that introduction of dopaminergic agonists could diminish these side effects while keeping the same efficacy as levodopa. Prospective clinical data do not support this idea with the present drugs. Levodopa remains the most useful treatment and most clinicians believe that it is wise to associate early on levodopa with one of the dopamine agonists.
authors.affiliation: Service de Neurologie, Hôpital Erasme, U.L.B., Bruxelles, Belgium. diederik.zegers.de.beyl@ulb.ac.be
authors.forename: Diederik
authors.initials: D
authors.lastname: Zegers de Beyl
mesh_terms: D000978:Antiparkinson Agents / Q000009:adverse effects*; D001921:Brain / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D004298:Dopamine / Q000378:metabolism; D018491:Dopamine Agonists / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy / Q000503:physiopathology / Q000517:prevention & control*; D006801:Humans; D007980:Levodopa / Q000009:adverse effects*; D009473:Neuronal Plasticity / Q000187:drug effects / Q000502:physiology; D010300:Parkinson Disease / Q000188:drug therapy*
chemical_list: D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D007980:Levodopa; D004298:Dopamine